Premier Gladys Berejiklian said the $250 million program from Investment NSW was an opportunity for the state to invest in its future prosperity by nurturing industries, technology and stimulating job creation.
“NSW is open for business – our world-leading management of the pandemic has made our state a premier destination for relocation and expansion,” Ms Berejiklian said.
“Jobs Plus is focused on propelling NSW into post-pandemic prosperity by incentivising the private sector to invest in job creation opportunities and support through the critical stages of business development.
“Supporting Baxter Healthcare and SpeeDx to take their NSW operations to the next level will support approximately 280 direct jobs in medical equipment manufacturing and biotechnology over the next four years.”
Baxter Healthcare, Australia’s only local manufacturer of intravenous (IV) medical fluids will invest in a major expansion of its advanced manufacturing facility in Western Sydney, supporting more than 600 existing jobs in NSW and creating approximately 80 new jobs by June 2024.
SpeeDx will look to establish a new global headquarters, including relocating manufacturing capabilities from the US to Sydney and improving supply chain bottlenecks, creating almost 200 jobs by June 2024.
Minister for Jobs, Investment, Tourism and Western Sydney Stuart Ayres said supporting the growth of medical technology and healthcare innovation protected lives as well as the economy.
“The pandemic put a spotlight on the value of these high-growth, essential industries and backing their growth is crucial to ensure our economy is fuelled by sustainable, knowledge-based jobs that are here for the long run,” Mr Ayres said.
“The Jobs Plus Concierge Service is helping businesses to navigate government agencies, programs and application requirements, making NSW the best place in the world to base or expand your business,” Mr Ayres said.
Baxter Healthcare General Manager for Australia and New Zealand, Steven Flynn said that the company was proud to partner with the NSW Government to invest in modern manufacturing operations in Western Sydney and create jobs in the local medtech sector.
“As Australia’s only local manufacturer of IV medical fluids, Baxter is committed to supporting our hospitals and healthcare professionals with reliable supply of medicines during the pandemic and beyond,” Mr Flynn said.
“This major expansion of our medical manufacturing facility in NSW will help to strengthen our national supply chain resilience and support continued export growth of Australian Made medicines.”
SpeeDx CEO Colin Denver said that the company had recently grown over 50% in just over a year, with continued growth planned for the NSW office with focus on the creation of innovative diagnostic tools that improve patient care in the field of infectious disease and antibiotic resistance.
“This government support comes at a pivotal time for the company, as we expand into new headquarters and significantly increase our manufacturing capacity, improve supply chain security and increase Australia's sovereign capacity for important diagnostic tests,” Mr Denver said.
The Jobs Plus Program provides eligible companies with support, including payroll tax relief, streamlined planning approval and subsidised training programs, as well as the provision of free or subsidised government spaces and accommodation.
Australian businesses that employ 20 or more staff and international companies with at least 80 employees looking to create a minimum of 30 jobs before June 2024 are eligible to apply for Jobs Plus.
To check your eligibility and find out more via the Jobs Plus Program.